Detalhe da pesquisa
1.
Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma.
Blood;
140(23): 2463-2476, 2022 12 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35960849
2.
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Blood;
134(16): 1323-1336, 2019 10 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31492675
3.
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Blood;
131(4): 421-425, 2018 01 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29187379
4.
Combination therapy of a PSEN1-selective γ-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia.
Haematologica;
108(9): 2507-2512, 2023 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36700404
5.
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
Haematologica;
102(9): 1605-1616, 2017 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28659337
6.
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Blood;
124(20): 3092-100, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25193870
7.
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
J Hematol Oncol;
14(1): 97, 2021 06 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34167562
8.
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.
Nat Commun;
12(1): 3705, 2021 06 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34140493
9.
The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia.
Clin Cancer Res;
26(21): 5747-5758, 2020 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32826328
10.
Oncogenic Cooperation Between IL7R-JAK-STAT Pathway Mutations.
Hemasphere;
5(9): e637, 2021 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34476346
11.
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
PLoS One;
11(1): e0146100, 2016.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26745281
12.
JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors.
Hemasphere;
3(6): e313, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31976485
13.
Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia.
Hemasphere;
3(6): e310, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31976483
14.
Identification of novel FLT3 kinase inhibitors.
Eur J Med Chem;
63: 713-21, 2013 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23567961
15.
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.
Nat Genet;
45(2): 186-90, 2013 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23263491